Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Heini Pharmaceutical is a prominent subsidiary of the Yangtze River Pharmaceutical Group (YRPG), established in 2001 and located in Shanghai's Pudong New Area. The company functions as a major research, development, and manufacturing hub for the group, specializing in high-end chemical pharmaceuticals and modern formulations. Its product portfolio is diverse, covering critical therapeutic areas such as cardiovascular health, gastroenterology, and anti-infectives. The facility maintains rigorous quality standards with multiple GMP-certified production lines for solid oral dosage forms, including tablets, capsules, and granules. As a key component of YRPG, Shanghai Heini Pharmaceutical contributes significantly to the group's domestic market leadership and its expanding global footprint. The company is strategically integrated into the Shanghai International Medical Zone, leveraging the region's robust biotech ecosystem for innovation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Yangtze River Pharmaceutical Group Shanghai Heini Pharmaceutical.